---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066915"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:37:59.811817+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Treace Q1 revenue $52.6M (+3% YoY); net loss improves to $(15.9)M; reaffirms FY2025 guidance

## Summary
- Revenue $52.6M, up 3% from $51.1M; adjusted for one less selling day, growth 4.5%.
- Net loss $(15.9)M ($(0.25)/share) vs $(18.7)M ($(0.30)/share) in Q1 2024, improved 15%.
- Adjusted EBITDA $(3.8)M, a 53% improvement from $(8.3)M in prior-year quarter.
- Reaffirms FY2025 revenue guidance $224-230M (7-10% growth) and breakeven adjusted EBITDA.
- Launched three new bunion systems (Nanoplasty, Percuplasty 3D MIS, SpeedMTP MTP Fusion).

## SEC filing metadata
- accession: 0000950170-25-066915
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017025066915/0000950170-25-066915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017025066915/tmci-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066915
- JSON: https://secwatch.observer/filing/0000950170-25-066915.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.